Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
IntraPace raises funds for obesity control implant: Clinical trials of IntraPace's endoscopically delivered, implantable gastric stimulator for treatment of obesity will commence in 2007, supported by a $30 mil. private placement announced Aug. 14, according to the company. The funds will be used to "complete product development and worldwide clinical studies," IntraPace says. Competing products under development include EnteroMedics' Maestro obesity management implant, in Phase I trials (1"The Gray Sheet" Aug. 7, 2006, p. 10). IntraPace's Series D financing round was led by Vulcan Capital. Additional investors include Boston Scientific, Johnson & Johnson, L Capital Partners, DFJ ePlanet, Oxford Bioscience Partners, Toucan Capital, CB Health Ventures, Halo Fund II and The Angel's Forum...